Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097341 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
A Phase 1 study, sponsored by Aronora.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03097341 is a Phase 1 study that has completed, run by Aronora. The registered enrollment target is 21 participants.
The verdict
NCT03097341, a Phase 1 study, has completed, sponsored by Aronora.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of xisomab 3G3 in healthy adult subjects.
Interventions
- OTHER Placebo
- DRUG xisomab 3G3- Dose 1
- DRUG xisomab 3G3-Dose 2
- DRUG xisomab 3G3-Dose 3
- DRUG xisomab 3G3- Dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2018-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03097341
The ClinicalTrials.gov registry entry for NCT03097341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aronora, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03097341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03097341 about?
NCT03097341 is a clinical study titled "Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects". The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of xisomab 3G3 in healthy adult subjects.
What is the current status of trial NCT03097341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-06-05. Estimated completion is 2018-01-16.
What interventions are being tested in trial NCT03097341?
The interventions under investigation include: Placebo (OTHER), xisomab 3G3- Dose 1 (DRUG), xisomab 3G3-Dose 2 (DRUG), xisomab 3G3-Dose 3 (DRUG), xisomab 3G3- Dose 4 (DRUG).
Who is sponsoring clinical trial NCT03097341?
This trial is sponsored by Aronora, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.